Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study

Diabetes Therapy

Volumn 6, Issue 2, 2015, Pages 173-185

  Mezquita Raya, Pedro ^a,b   Reyes Garcia, Rebeca ^b,c   Moreno Perez, Oscar ^d   Escalada San Martin, Javier ^e   Ángel Rubio Herrera, Miquel ^f   Lopez de la Torre Casares, Martin ^g  

^a Unidad de Endocrinología Nutrición y Riesgo Vascular Complejo Hospitalario Torrecárdenas   (Spain)

^b Servicio de Endocrinología Clínica San Pedro   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Effectiveness; Liraglutide; Real life; Type 2 diabetes

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; REPAGLINIDE; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG DOSE ESCALATION; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPAIN; SYSTOLIC BLOOD PRESSURE;

EID: 84935001656     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-015-0112-4     Document Type: Article

References (23)

1. Mezquita Raya P, Reyes García R. Is treatment with liraglutide efficient? Endocrinol Nutr. 2014;61:202–8.
2. AACE/ACE Comprehensive Diabetes Management Algorithm. https://www.aace.com/files/aace_algorithm.pdf. Accessed Apr 10, 2015.
3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD), et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9.
4. Reyes García R, Mezquita Raya P. How to prevent and treat pharmacological hypoglycaemias. Rev Clin Esp. 2014;214:202–8.
5. Mezquita-Raya P, Reyes-García R, Moreno-Pérez Ó, Muñoz-Torres M, Merino-Torres JF, Gorgojo-Martínez JJ, et al. Position statement: hypoglycaemia management in patients with diabetes mellitus. Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition. Endocrinol Nutr. 2013;60:517.e1–18.
6. Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, LEAD-1 SU Study Group, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268–78.
7. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Effectiveness and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care. 2009;32:84–90.
8. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes(LEAD-3 mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–81.
9. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. LEAD-4 Study Investigators. Effectiveness and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care. 2009;32:1224–30.
10. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met + SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52:2046–55.
11. Rigato M, Fadini GP. Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2014;7:107–20.
12. Mezquita Raya P, Pérez A, Ramírez de Arellano A, Briones T, Hunt B, Valentine WJ. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. Diabetes Ther. 2013;4:417–30.
13. Evans M, McEwan P, O’Shea R, George L. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice. Diabetes Ther. 2013;4:27–40.
14. Fadini GP, Simioni N, Frison V, Dal Pos M, Bettio M, Rocchini P, et al. Independent glucose and weight reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients. Acta Diabetol. 2013;50:943–9.
15. Mulligan CM, Harper R, Harding J, McIlwaine W, Petruckevitch A, McLaughlin DM. A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice. Diabetes Ther. 2013;4:147–51.
16. Heymann A, Maor Y, Goldstein I, Todorova L, Schertz-Sternberg P, Karasik A. Efficacy of liraglutide in a real-life cohort. Diabetes Ther. 2014;5:193–206.
17. Chitnis AS, Ganz ML, Benjamin N, Langer J, Hammer M. Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study. Adv Ther. 2014;31:986–99.
18. Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B, LEAD-3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:348–56.
19. Charpentier G, Martinez L, Eschwège E, Madani S, Penfornis A, Gourdy P, et al. Effectiveness of the human GLP-1 analogue liraglutide in patients with type 2 diabetes who switched from a DPP-4 inhibitor: 1-year data from the EVIDENCE study. Diabetologia. 2013;56(Suppl 1):S358.
20. Violante R, Oliveira JH, Yoon KH, Reed VA, Yu MB, Bachmann OP, et al. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin. Diabet Med. 2012;29:e417–24.
21. Zinman B, Schmidt WE, Moses A, Lund N, Gough S. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012;14:77–82.
22. Jansen HJ, Vervoort GM, de Haan AF, Netten PM, de Grauw WJ, Tack CJ. Diabetes-related distress, insulin dose, and age contribute to insulin-associated weight gain in patients with type 2 diabetes: results of a prospective study. Diabetes Care. 2014;37:2710–7.
23. Pérez A, Mediavilla JJ, Miñambres I, González-Segura D. Glycemic control in patients with type 2 diabetes mellitus in Spain. Rev Clin Esp. 2014;214:429–36.